To The Moon

Hong Kong Stocks Are Trying to Stabilise. I’m Watching 2 Very Different Opportunities!

After 2 difficult weeks, Hong Kong stocks have given investors a reason to look again at valuations. But I would not call a brief rebound a market bottom just yet.

The Hang Seng Index dropped below 23,000 intraday on 22 October, while the Hang Seng TECH Index came under renewed pressure. By 29 October, the Hang Seng Index had recovered to around 23,100, but the Hang Seng TECH Index was still trading below 3,800 and fell again that day.

To me, this is a reminder that a stabilising headline index does not mean every part of the market has recovered.

Instead of trying to predict the next market-wide move, I would focus on two areas that have attracted attention: innovative drug and pharmaceutical outsourcing companies, and mainland Chinese bank stocks with dividend appeal.

They offer very different investment propositions. One depends heavily on business growth and future earnings; the other is more closely tied to profitability, capital strength and the sustainability of distributions.

1. Biopharma: the opportunity needs to be backed by earnings

The pharmaceutical services sector has a fresh fundamental catalyst in WuXi AppTec (2359.HK / 603259.SH).

Its latest results for the first nine months of 2026 showed revenue of RMB45.54 billion, up 38.6% year over year. Adjusted non-IFRS net profit rose 74.4% to RMB18.38 billion, while its backlog for continuing operations reached RMB76.74 billion, an increase of 36.4%.

These are meaningful numbers because they show growth in revenue, profitability and contracted future work, rather than a share-price rally driven entirely by sentiment.

The company also raised its full-year guidance. That gives investors a concrete reason to reassess its earnings outlook.

However, I would be careful about extending WuXi AppTec’s results to the entire biotech sector. Innovative drug developers, clinical research organisations and contract development and manufacturing companies have different business models. A strong quarter from a pharmaceutical services provider does not guarantee that drug developers will deliver successful clinical trials or commercial sales.

For this group, I would look at order growth, backlog conversion, margins, cash flow and customer demand. For drug developers, I would focus more on clinical milestones, regulatory decisions, commercial prospects and funding needs.

The key question is whether improving fundamentals can support today’s valuation, not whether the sector has already fallen enough.

2. Mainland bank dividend stocks: income is attractive, but it is not guaranteed

The second area I would watch is mainland Chinese banks, including large state-owned lenders listed in Hong Kong.

Their appeal is different from that of high-growth technology or biotech stocks. Investors may be attracted by their established franchises, profitability and dividend distributions, particularly when market volatility makes speculative growth less appealing.

But a high dividend yield should never be the entire investment thesis.

A stock’s yield can rise simply because its share price has fallen. That may create an opportunity, but it can also reflect concerns about future earnings, asset quality or the sustainability of the dividend.

For banks, I would examine several things before buying:

* Net interest margin: Are lending margins stabilising, or is pressure from loan pricing and funding costs continuing?

* Asset quality: Are non-performing loans and credit-loss provisions manageable, particularly in a weak economic environment?

* Capital strength: Does the bank have sufficient capital to absorb potential losses while maintaining its business?

* Dividend sustainability: Are distributions supported by earnings and capital generation, rather than simply an attractive historical payout?

* Valuation: Does the share price adequately compensate investors for the risks?

There is also an important distinction between dividend income and total return. A bank can pay dividends while its share price declines. Investors should consider both the income received and the potential change in the value of their holdings.

I would view these stocks as potential income-oriented investments, not as risk-free substitutes for cash or deposits.

3. Has market sentiment bottomed?

I would not use one or two positive trading sessions to declare that the correction is over.

The Federal Reserve kept its target range at 3.75%–4.00% on 28 October, but it also noted that inflation remains elevated. The decision removed the immediate uncertainty around that meeting; it did not eliminate uncertainty over future policy or the outlook for global risk assets.

For Hong Kong stocks, I would watch whether the market can hold its recent lows, whether turnover improves on advances, and whether gains spread beyond a small number of popular sectors.

I would also pay attention to the quality of the rebound. If prices rise while earnings estimates continue to deteriorate, the recovery may prove fragile. If prices stabilise alongside improving company results and more constructive guidance, the case becomes stronger.

Neither outcome can be confirmed from a single day’s price action.

4. How I would approach this window of opportunity

I would not buy both themes for the same reason.

For pharmaceutical services and innovative drug companies, I would be looking for businesses where the growth outlook is supported by measurable operating progress, with valuation and execution risks properly considered.

For mainland bank dividend stocks, I would prioritise balance-sheet resilience, asset quality, sustainable distributions and a reasonable entry valuation.

I would also avoid deploying all available capital simply because prices have fallen. Buying in stages can reduce the pressure to make one perfect timing decision, although it does not guarantee a better return. If the market rebounds quickly, staged purchases may mean paying more later; if it falls further, retaining cash provides flexibility.

Most importantly, I would not assume that every stock in either theme is a bargain. Sector strength can attract momentum-driven money, and popular trades can become expensive surprisingly quickly.

My takeaway

Hong Kong stocks may be entering a period of sentiment recovery, but I would treat that as a possibility to test rather than a conclusion to trade on.

WuXi AppTec’s results show why individual company fundamentals matter during a sell-off. Mainland bank dividends offer a different proposition, but investors still need to check whether the income is sustainable and whether the valuation compensates for credit and earnings risks.

For me, the best opportunities are not necessarily the stocks that have fallen the most or the sectors that rebound first. They are the businesses where the facts support the investment thesis and the price leaves enough room for the risks.

Would you rather look for growth in pharmaceutical and biotech stocks, or dividend income from mainland banks at current valuations? 

What evidence would convince you that Hong Kong’s rebound is becoming more durable?

$HSI(HSI)$  $ICBC(01398)$  $CCB(00939)$  $ABC(01288)$  

$WUXI APPTEC(02359)$